Failed early
Abatacept: reduce relapses and new lesions in relapsing and progressive MS
relapsing and progressive MS · T-cell co-stimulation / cytokine targeting
Controlled phase 2 trials were negative.
- Trials
- 1
- Running now
- 0
- Controlled phase 2/3 trials
- 1
- People in controlled trials
- 0
Deciding trials (phase 2): 0 met, 1 did not.
Other linked trials: 0
Dose comparisons, trials against another medicine, add-on trials, phase 1 and uncontrolled studies. They are listed below but do not set the status.
Human genetics
Genes linked to MS that these medicines act on: CD86
Trials
- A Study to Evaluate the Preliminary Efficacy Pharmacokinetics and Immunogenicity of BMS-188667 Administered to Subjects With Relapsing-remitting Multiple Sclerosisdecides the statusMissed main goal
Phase 2 · 2001 · Placebo-controlled · MSFT-NCT00035529
No statistically significant differences were observed in mean number of new Gd+ MRI lesions between the abatacept and placebo groups.
Read by software from the paper's abstract
The deciding phase and counts come from the Trial Bank’s fixed rules.
Lab evidence
Lab studies in animals or cells. Results in animals often do not hold in people, and these studies never change the status of an idea.
Loading lab studies…
Loading reviews and guidelines…
History
- 2026-10-28Status changed from No clear answer to Failed early
- 2026-10-27First listed as No clear answer
Related hypotheses
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error